I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).

I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.

Iovance (SYM: IOVA) jumped 20% today after announcing news that its lung cancer candidate LN-145 could be acceptable for a potential accelerated approval.

We have a strong group of stocks, so I want to take today to highlight some of the best opportunities I haven’t talked about recently (and update others).

A lot of newer members have written in to ask about Iovance Biotherapeutics (SYM: IOVA).

Two things I want to discuss this week…

We haven’t talked about Iovance Bio (SYM: IOVA) in a while. I figured I’d use this issue to update you on it, since there were slim pickins’ out there this week anyway.

Every year, millions of lives are irrevocably changed as they grapple with the devastating impacts of a cancer diagnosis.

Growth stocks have been universally hammered in the past few months as the market quickly declined due to higher economic uncertainty, inflation, and interest rates. As many seasoned investors know, it’s during times like this when strong long-term investment returns are made.

I like the team that runs Diamondback Energy.